1978 1980 1981 1982 1983 1984

1985 1986 1987 1988 1989 1990

1992 1993 1994 1995 1996 1997

1998 1999 2000 2001 2002 2003

2004 2005 2006 2007 2008

Current evaluation of the tissue localization and diagnostic utility of prostate specific membrane antigen.
Murphy GP, Elgamal AA, Su SL, Bostwick DG, Holmes EH.

Prostate cancer microvessels: a novel method for three-dimensional reconstruction and analysis.
Kay PA, Robb RA, Bostwick DG.

Predictors of survival for prostate carcinoma patients treated with salvage radical prostatectomy after radiation therapy.
Cheng L, Sebo TJ, Slezak J, Pisansky TM, Bergstralh EJ, Neumann RM, Iczkowski KA, Zincke H, Bostwick DG.

Leydig cell tumor of the testis: a clinicopathologic, DNA content, and MIB-1 comparison of nonmetastasizing and metastasizing tumors.
Cheville JC, Sebo TJ, Lager DJ, Bostwick DG, Farrow GM.

Independent origin of multiple foci of prostatic intraepithelial neoplasia: comparison with matched foci of prostate carcinoma.
Bostwick DG, Shan A, Qian J, Darson M, Maihle NJ, Jenkins RB, Cheng L.

The pathologist as optimist: cancer grade deflation in prostatic needle biopsies.
Iczkowski KA, Bostwick DG.

Determination of gene and chromosome dosage in prostatic intraepithelial neoplasia and carcinoma.
Qian J, Jenkins RB, Bostwick DG.

Practical clinical application of predictive factors in prostate cancer. A review with an emphasis on quantitative methods in tissue specimens.
Bostwick DG.

Prostate-specific membrane antigen expression is greatest in prostate adenocarcinoma and lymph node metastases.
Sweat SD, Pacelli A, Murphy GP, Bostwick DG.

ProstAsure Index in the detection of prostate cancer.
Burke HB, Bostwick DG.

Malignant lymphoma involving the prostate: report of 62 cases.
Bostwick DG, Iczkowski KA, Amin MB, Discigil G, Osborne B.

Inhibin A is a sensitive and specific marker for testicular sex cord-stromal tumors.
Iczkowski KA, Bostwick DG, Roche PC, Cheville JC.

High grade prostatic intraepithelial neoplasia in military working dogs with and without prostate cancer.
Aquilina JW, McKinney L, Pacelli A, Richman LK, Waters DJ, Thompson I, Burghardt WF Jr, Bostwick DG.

Microvessel density in prostate cancer: prognostic and therapeutic utility.
Bostwick DG, Iczkowski KA.

Long-term follow-up of untreated stage T1a prostate cancer.
Cheng L, Neumann RM, Blute ML, Zincke H, Bostwick DG.

Workgroup I: rodent models of prostate cancer.
Lucia MS, Bostwick DG, Bosland M, Cockett AT, Knapp DW, Leav I, Pollard M, Rinker-Schaeffer C, Shirai T, Watkins BA.

Conference summary: First International Workshop on Animal models of Prostate Cancer.
Waters DJ, Bostwick DG, Murphy GP.

Prostate specific membrane antigen expression in prostatic intraepithelial neoplasia and adenocarcinoma: a study of 184 cases.
Bostwick DG, Pacelli A, Blute M, Roche P, Murphy GP.

Expression of early growth response genes in human prostate cancer.
Eid MA, Kumar MV, Iczkowski KA, Bostwick DG, Tindall DJ.

Detection of early prostate cancer: serendipitous or systematic?
Iczkowski KA, Bostwick DG.

Prostatic adenocarcinoma with glomeruloid features.
Pacelli A, Lopez-Beltran A, Egan AJ, Bostwick DG.

Carcinosarcoma and sarcomatoid carcinoma of the bladder: clinicopathological study of 41 cases.
Lopez-Beltran A, Pacelli A, Rothenberg HJ, Wollan PC, Zincke H, Blute ML, Bostwick DG.

Influence of prostate-specific antigen testing on the spectrum of patients with prostate cancer undergoing radical prostatectomy at a large referral practice.
Amling CL, Blute ML, Lerner SE, Bergstralh EJ, Bostwick DG, Zincke H.

Diagnosis of "suspicious for malignancy" in prostate biopsies: predictive value for cancer.
Iczkowski KA, Bassler TJ, Schwob VS, Bassler IC, Kunnel BS, Orozco RE, Bostwick DG.

Loss of CD44 variant 6 expression differentiates small cell carcinoma of urinary bladder from urothelial (transitional cell) carcinoma.
Iczkowski KA, Shanks JH, Bostwick DG.

Expression of p27kip1 in prostatic adenocarcinoma.
Cheville JC, Lloyd RV, Sebo TJ, Cheng L, Erickson L, Bostwick DG, Lohse CM, Wollan P.

Prevalence of a physician-assigned diagnosis of prostatitis: the Olmsted County Study of Urinary Symptoms and Health Status Among Men.
Roberts RO, Lieber MM, Rhodes T, Girman CJ, Bostwick DG, Jacobsen SJ.

Pathologic classification of prostate carcinoma: the impact of margin status.
Blute ML, Bostwick DG, Seay TM, Martin SK, Slezak JM, Bergstralh EJ, Zincke H.

Transitional cell carcinoma of the prostate: clinicopathologic study of 50 cases.
Cheville JC, Dundore PA, Bostwick DG, Lieber MM, Batts KP, Sebo TJ, Farrow GM.

A molecular cytogenetic analysis of 7q31 in prostate cancer.
Jenkins RB, Qian J, Lee HK, Huang H, Hirasawa K, Bostwick DG, Proffitt J, Wilber K, Lieber MM, Liu W, Smith DI.

Atypical adenomatous hyperplasia of the prostate: a premalignant lesion?
Cheng L, Shan A, Cheville JC, Qian J, Bostwick DG.

Diagnosis and prognosis of renal cell carcinoma: highlights from an international consensus workshop.
Bostwick DG, Murphy GP.

Prostatic adenocarcinoma following androgen deprivation therapy: the new difficulty in histologic interpretation.
Bostwick DG.

Prediction of patient outcome in pathologic stage T2 adenocarcinoma of the prostate: lack of significance for microvessel density analysis.
Gettman MT, Bergstralh EJ, Blute M, Zincke H, Bostwick DG.